- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| 06.05. | Azitra receives U.S. patent for Netherton syndrome treatment | 1 | Investing.com | ||
| 06.05. | Azitra secures U.S. patent for ATR-12 skin disease treatment program | 2 | Seeking Alpha | ||
| 23.03. | Azitra, Inc. - 8-K, Current Report | 2 | SEC Filings | ||
| AZITRA Aktie jetzt für 0€ handeln | |||||
| 20.03. | Azitra Shares Jump 55% | 3 | RTTNews | ||
| 20.03. | Azitra CEO-backed private placement priced up to $10.5M, potential $20.9M; stock jumps 90% | 3 | Seeking Alpha | ||
| 19.03. | Azitra secures up to $31.4M to fund cosmetic protein research | 2 | Investing.com | ||
| 19.03. | Azitra sichert sich bis zu 31,4 Mio. USD zur Finanzierung kosmetischer Proteinforschung | 10 | Investing.com Deutsch | ||
| 13.03. | Azitra, Inc.: Azitra Receives Notice of Non-Compliance from NYSE American and Makes NYSE American Section 610(b) Public Announcement | 457 | PR Newswire | BRANFORD, Conn., March 13, 2026 /PRNewswire/ -- Azitra, Inc. (NYSE American: AZTR), a clinical stage biopharmaceutical company focused on developing innovative... ► Artikel lesen | |
| 13.03. | NYSE warnt Azitra vor Delisting aufgrund von Eigenkapitaldefizit | 2 | Investing.com Deutsch | ||
| 13.03. | Azitra receives notice of non-compliance with NYSE American Listing standards | 2 | Seeking Alpha | ||
| 13.03. | Azitra receives NYSE delisting warning over equity shortfall | 1 | Investing.com | ||
| 13.03. | Azitra, Inc. - 8-K, Current Report | 1 | SEC Filings | ||
| 27.02. | Azitra GAAP EPS of -$2.25 beats by $0.23 | 3 | Seeking Alpha | ||
| 27.02. | Azitra, Inc. Announces Full Year 2025 Results and Provides Business Updates | 488 | PR Newswire | BRANFORD, Conn., Feb. 27, 2026 /PRNewswire/ -- Azitra, Inc. ("Azitra") (NYSE American: AZTR), a clinical stage biopharmaceutical company focused on developing innovative... ► Artikel lesen | |
| 27.02. | Azitra, Inc. - 8-K, Current Report | 1 | SEC Filings | ||
| 27.02. | Azitra, Inc. - 10-K, Annual Report | 1 | SEC Filings | ||
| 06.02. | Azitra, Inc. - 8-K, Current Report | 1 | SEC Filings | ||
| 30.01. | Azitra, Inc. - S-8, Securities to be offered to employees in employee benefit plans | 3 | SEC Filings | ||
| 17.12.25 | Azitra receives NYSE American approval of listing compliance plan | 1 | Seeking Alpha | ||
| 17.12.25 | Azitra receives approval for NYSE American compliance plan | 3 | Investing.com |
1 2 Weiter >>
34 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| QIAGEN | 28,350 | -1,56 % | Qiagen erhöht Dividende und stellt weitere Aktienrückkäufe in Aussicht | DJ Qiagen erhöht Dividende und stellt weitere Aktienrückkäufe in Aussicht
DOW JONES--Die Aktionäre von Qiagen können sich über eine höhere Dividende freuen. Wie es in der Einladung zur Hauptversammlung... ► Artikel lesen | |
| EVOTEC | 4,540 | -10,63 % | EQS-News: Evotec SE: Evotec gibt Ergebnisse für das erste Quartal 2026 bekannt: Transformation gewinnt an Dynamik | EQS-News: Evotec SE
/ Schlagwort(e): Quartalsergebnis/Quartals-/Zwischenmitteilung
Evotec gibt Ergebnisse für das erste Quartal 2026 bekannt: Transformation gewinnt an Dynamik... ► Artikel lesen | |
| RELAY THERAPEUTICS | 13,220 | +2,24 % | H.C. Wainwright is Bullish on Relay Therapeutics, Inc. (RLAY) | ||
| TARSUS PHARMACEUTICALS | 64,66 | +8,07 % | Tarsus reiterates 2026 net product sales guidance of $670M-$700M as XDEMVY posts $145.4M in Q1 sales | ||
| BICARA THERAPEUTICS | 20,990 | 0,00 % | Bicara Therapeutics Inc.: Bicara Therapeutics Reports First Quarter 2026 Financial Results and Provides Business Update | Study to evaluate ficerafusp alfa in combination with pembrolizumab as a loading and every-three-week maintenance regimen in 1L R/M HPV-negative HNSCC expected to initiate in Q3 2026 Long-term follow-up... ► Artikel lesen | |
| ARCUTIS BIOTHERAPEUTICS | 21,690 | +4,83 % | Arcutis Q1 2026: Umsatz steigt um 65 %, doch Expansionskosten führen zu höheren Verlusten | ||
| PRAXIS PRECISION MEDICINES | 346,46 | +0,95 % | Praxis Precision Medicines, Inc.: Praxis Precision Medicines Provides Corporate Update and Reports First Quarter 2026 Financial Results | FDA accepted the new drug application (NDA) for ulixacaltamide in Essential Tremor with a PDUFA target action date of January 29, 2027, and the NDA for relutrigine, with priority review, in SCN2A... ► Artikel lesen | |
| ALLOGENE THERAPEUTICS | 2,330 | +1,30 % | Allogene Therapeutics, Inc.: Allogene Therapeutics Reports First Quarter 2026 Financial Results and Business Update | ||
| TANGO THERAPEUTICS | 25,510 | +8,55 % | Stifel Remains Bullish on Tango Therapeutics (TNGX) | ||
| C4 THERAPEUTICS | 3,660 | +15,46 % | C4 Therapeutics, Inc.: C4 Therapeutics Reports First Quarter 2026 Financial Results and Recent Business Highlights | Progressed Plans to Establish Cemsidomide as a Potentially Foundational Treatment for Multiple Myeloma; Enrollment Ongoing in Phase 2 MOMENTUM Trial and Phase 1b Trial in Combination with Elranatamab... ► Artikel lesen | |
| BIONTECH | 78,95 | -1,07 % | Curevac-Gründer wirft Biontech Täuschung vor | TÜBINGEN/MAINZ (dpa-AFX) - Nach der Übernahme des Biotechunternehmens Curevac durch Biontech wirft Curevac-Gründer Ingmar Hoerr dem Konkurrenten Täuschung vor. Hintergrund sind die Schließungspläne... ► Artikel lesen | |
| INHIBRX BIOSCIENCES | 117,82 | +8,44 % | Inhibrx Biosciences, Inc.: Inhibrx Reports Interim Phase 2 Data for INBRX-106 in First-Line HNSCC; Initial Results Demonstrate Potential Costimulatory Benefit Over PD-1 Monotherapy | Interim analyses show INBRX-106 + pembrolizumab achieved a 44.0% confirmed Objective Response Rate (cORR): In the preliminary confirmed response-evaluable population... ► Artikel lesen | |
| BIOVENTUS | 10,400 | +2,56 % | Bioventus, Inc.: Bioventus Reports First Quarter Financial Results | Q1 reported revenue of $132.1 million increased 7%First quarter GAAP earnings of $0.04 per diluted share compared to the prior-year period loss of $0.04 per diluted shareNon-GAAP earnings* of $0.15... ► Artikel lesen | |
| MINERALYS THERAPEUTICS | 26,850 | -8,24 % | Mineralys Therapeutics, Inc.: Mineralys Therapeutics Reports First Quarter 2026 Financial Results and Provides Corporate Update | - NDA for lorundrostat in adults with hypertension accepted by FDA; assigned PDUFA target date of December 22, 2026 - - Conference call today at 4:30 p.m. ET - RADNOR, Pa., May 06, 2026 (GLOBE NEWSWIRE)... ► Artikel lesen | |
| ERASCA | 10,450 | +0,67 % | Erasca, Inc.: Erasca Reports First Quarter 2026 Business Updates and Financial Results | Robust monotherapy efficacy and generally well-tolerated safety results observed during dose escalation for ERAS-0015 in both KRAS G12X NSCLC and PDAC reinforce best-in-class potential across RAS-targeted... ► Artikel lesen |
AZITRA INC gehört der Branche Biotechnologie an. Mit einer aktuellen Kursveränderung von 0,000 (0,00 %) liegt der Kurs bei 0,220 Euro.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und sowie Kurse und Daten von ARIVA.DE AG.
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu AZITRA INC finden Sie auf Wallstreet Online.